广济药业：预计2025年归母净利润为亏损5.18亿元至3.99亿元

Core Viewpoint - Guangji Pharmaceutical expects a net profit loss attributable to shareholders of between 518 million yuan and 399 million yuan for the fiscal year 2025, compared to a loss of 295 million yuan in the same period last year [1] Group 1: Financial Performance - The company is projected to experience a significant increase in net losses, indicating a worsening financial situation [1] - The anticipated loss range for 2025 represents a deterioration compared to the previous year's loss [1] Group 2: Market Conditions - The pharmaceutical industry is facing intensified market competition, which has adversely affected the company's pricing power [1] - The sales prices of the company's main products have remained low and have not shown signs of recovery during the reporting period [1] Group 3: Operational Performance - The company's capacity utilization and overall operational performance have not met expectations, contributing to ongoing operational losses [1]